by administrator | Aug 25, 2016 | IMV Inc., News
See original news release here Halifax, Nova Scotia; August 25, 2016 – Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced new data from its Phase 1/1b trial in ovarian cancer, which reinforced previously...
by administrator | Jul 6, 2016 | IMV Inc., News
here Vaccine Demonstrated Tolerable Safety Profile, Induced Measurable Immunogenic Response in 100 Percent of Study Participants in Higher Dose Cohort Trial Provides Immunovaccine’s First Clinical Immunogenicity Demonstration in Infectious Disease Applications ...
by administrator | Apr 21, 2016 | DSM, IMV Inc., Innovative Medicines Canada, News
NEWS RELEASE HALIFAX, April 21, 2016 — On Tuesday the Nova Scotia government tabled its 2016-17 Budget with a surplus of $17.1 million and a commitment to work collaboratively with industries with big potential in the province. As part of the Budget address, the...
